438245-97-7

Usage

Uses

Used in Pharmaceutical Industry:
Benzenemethanamine, 3-methoxy-N,alpha-dimethyl(9CI) is used as a research chemical for the development of new medications and therapies. Its psychoactive properties make it a valuable compound for studying the effects of stimulants and entactogens on the human brain and nervous system.
Used in Forensic Science:
Benzenemethanamine, 3-methoxy-N,alpha-dimethyl(9CI) is utilized in forensic science for the identification and analysis of controlled substances in cases involving drug abuse and addiction. Its unique chemical structure allows for accurate detection and differentiation from other similar compounds.
Used in Recreational Settings:
Although it is considered a controlled substance in many countries, Benzenemethanamine, 3-methoxy-N,alpha-dimethyl(9CI) has been used recreationally for its psychoactive properties, providing users with stimulant and entactogenic effects. However, its potential for abuse and addiction makes it a substance that requires strict regulation and control.

InChI:InChI=1/C10H15NO/c1-8(11-2)9-5-4-6-10(7-9)12-3/h4-8,11H,1-3H3

Upstream product

• 74-89-5 methylamine 
• 586-37-8 1-(3-Methoxyphenyl)ethanone 
• 50919-07-8 1-(3-methoxy-phenyl)-ethylamine 
• 205701-99-1 N-formyl-1-(3-methoxyphenyl)ethylamine 
• 118761-92-5 N-methyl-[1-(3'-methoxylphenyl)ethylidene]amine 

Downstream Products

• 903588-34-1 tert-butyl 3-((1-(3-methoxyphenyl)ethyl)(methyl)amino)propylcarbamate 
• 903588-35-2 N₁-(1-(3-methoxyphenyl)ethyl)-N₁-methylpropane-1,3-diamine 
• 903588-28-3 5-(1,2-dithiolan-3-yl)-N-(3-((1-(3-methoxyphenyl)ethyl)(methyl)amino) propyl) pentanamide 
• 929048-90-8 2-(3,4,5-trimethoxyphenyl)-2-acetoxy-N-methyl-N-(1-(3-methoxyphenyl)ethyl)-acetamide 
• 923035-06-7 3-((1-methylamino)ethyl)phenol 
• 925201-40-7 (S)-α-3-methoxyphenylethylmethylamine dibenzoyl-L-tartrate 

Relevant academic research and scientific papers

Oxidation Under Reductive Conditions: From Benzylic Ethers to Acetals with Perfect Atom-Economy by Titanocene(III) Catalysis

Described here is a titanocene-catalyzed reaction for the synthesis of acetals and hemiaminals from benzylic ethers and benzylic amines, respectively, with pendant epoxides. The reaction proceeds by catalysis in single-electron steps. The oxidative addition comprises an epoxide opening. An H-atom transfer, to generate a benzylic radical, serves as a radical translocation step, and an organometallic oxygen rebound as a reductive elimination. The reaction mechanism was studied by high-level dispersion corrected hybrid functional DFT with implicit solvation. The low-energy conformational space was searched by the efficient CREST program. The stereoselectivity was deduced from the lowest lying benzylic radical structures and their conformations are controlled by hyperconjugative interactions and steric interactions between the titanocene catalyst and the aryl groups of the substrate. An interesting mechanistic aspect is that the oxidation of the benzylic center occurs under reducing conditions.

Disulfonimide-Catalyzed Asymmetric Reduction of N-Alkyl Imines

A chiral disulfonimide (DSI)-catalyzed asymmetric reduction of N-alkyl imines with Hantzsch esters as a hydrogen source in the presence of Boc2O has been developed. The reaction delivers Boc-protected N-alkyl amines with excellent yields and enantioselectivity. The method tolerates a large variety of alkyl amines, thus illustrating potential for a general reductive cross-coupling of ketones with diverse amines, and it was applied in the synthesis of the pharmaceuticals (S)-Rivastigmine, NPS R-568 Hydrochloride, and (R)-Fendiline. A chiral disulfonimide (DSI)-catalyzed asymmetric reduction of N-alkyl imines with Hantzsch esters as a hydrogen source in the presence of Boc2O was developed. The reaction delivers Boc-protected N-alkyl amines with excellent yields and enantioselectivity. The method was successfully applied to the synthesis of the pharmaceuticals (S)-Rivastigmine, NPS R-568 Hydrochloride, and (R)-Fendiline.

Isoquinolines as IGF-1R Inhibitors

Compounds of the formula (I): were synthesized. In at least one embodiment, they were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.

METHOD OF OBTAINING PHENYL CARBAMATES

The invention relates to a method of obtaining phenyl carbamates (I), wherein R 1 is lower alkyl C 1 -C 5 or benzyl and R 2 is methyl, ethyl or propyl, consisting in reacting L-(S)-3-[(1-methylamino)ethyl]phenol, in the presence of a base, with a carbamoyl halide in order to obtain an intermediate and, subsequently, subjecting said intermediate to a reducing amination reaction or a methylation reaction by reacting same with a methyl halide. The above-mentioned compounds (I) include rivastigmine, a compound that inhibits cholinesterase in the central nervous system, and can be used in the treatment of neurodegenerative diseases (E.g. senile dementia and Alzheimer's disease).

ISOQUINOLINES AS IGF-1R INHIBITORS

Compounds of the formula (I) were synthesized. They were found to down- regulate or inhibit the expression or function of the IGF-I receptor.